Yvonne Greenstreet Sells 15,650 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 15,650 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the completion of the sale, the chief executive officer owned 65,409 shares in the company, valued at $29,675,409.21. This represents a 19.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Yvonne Greenstreet also recently made the following trade(s):

• On Thursday, October 2nd, Yvonne Greenstreet sold 8,924 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $452.05, for a total transaction of $4,034,094.20.
• On Monday, August 18th, Yvonne Greenstreet sold 6,979 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $453.27, for a total value of $3,163,371.33.

Alnylam Pharmaceuticals Trading Down 1.1%

NASDAQ:ALNY traded down $4.81 during trading hours on Friday, reaching $449.16. 968,529 shares of the company were exchanged, compared to its average volume of 996,171. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The firm has a market cap of $59.34 billion, a price-to-earnings ratio of -181.85 and a beta of 0.30. The stock has a 50 day simple moving average of $458.86 and a 200 day simple moving average of $381.74. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Root Financial Partners LLC bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $25,000. SVB Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $27,000. Salomon & Ludwin LLC bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $27,000. Atlantic Union Bankshares Corp bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $30,000. Finally, Ameriflex Group Inc. bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $32,000. Institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ALNY shares. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research note on Tuesday. UBS Group increased their price objective on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Truist Financial lifted their target price on Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Scotiabank upped their price target on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a “sector outperform” rating in a research note on Friday, August 1st. Finally, Canaccord Genuity Group lifted their target price on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Twenty-three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $482.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.